The KEAP1 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the 769-P human renal cell carcinoma line, engineered to disrupt the KEAP1 gene locus. This product provides a heterogeneous pool of edited cells suitable for studying loss-of-function phenotypes in a cancer-relevant epithelial background. The polyclonal format enables researchers to assess population-level responses to KEAP1 disruption without clonal selection artifacts, while CRISPR/Cas9-mediated gene disruption generates a functional knockout model for the KEAP1-encoded protein.
The host cell line, 769-P, is an established epithelial cell line originally derived from a primary clear cell adenocarcinoma of the kidney. This widely used in vitro model retains characteristics of renal cell carcinoma, including relevant oncogenic signaling alterations and metabolic features. Grown under standard culture conditions, 769-P cells provide a clinically pertinent platform for investigating molecular mechanisms underlying renal tumorigenesis and therapy resistance.
KEAP1 functions as a substrate recognition subunit of the CUL3?CRBX1 E3 ubiquitin ligase complex, constitutively targeting the transcription factor NRF2 for ubiquitin-dependent proteasomal degradation. Under basal conditions, KEAP1 acts as a redox sensor, with oxidative stress or electrophilic stimuli modifying critical cysteine residues to inhibit its ligase activity, thereby allowing NRF2 stabilization and nuclear accumulation. Activated NRF2 heterodimerizes with small MAF proteins and binds to antioxidant response elements (ARE) in promoters of cytoprotective genes, including NQO1, HMOX1, GCLC, GCLM, and TXNRD1, orchestrating an antioxidant and detoxification response. KEAP1 also interacts with p62/SQSTM1, which competitively binds KEAP1 to release NRF2, and is regulated by upstream pathways such as PI3K-AKT. Knockout of KEAP1 leads to persistent NRF2-driven transcription and metabolic reprogramming.
In the context of renal cell carcinoma, KEAP1 inactivation is particularly relevant, as aberrant NRF2 activation promotes tumor cell survival, chemoresistance, and metabolic adaptation. The 769-P KEAP1 knockout model thus mirrors a scenario of constitutive NRF2 signaling, facilitating studies on how renal cancer cells cope with oxidative stress, evade ferroptosis, and acquire drug tolerance. Given that KEAP1 mutations or loss are observed in various cancers, including lung adenocarcinoma, this model extends its utility to cross-cancer comparisons of NRF2-dependent phenotypes.
Researchers can employ this polyclonal knockout cell population in a diverse array of experimental workflows. Typical applications include Western blot and RT-qPCR analysis of NRF2 and its target genes (e.g., NQO1, HMOX1), ARE luciferase reporter assays to measure transcriptional activity, immunofluorescence for NRF2 nuclear localization, and flow cytometry to quantify reactive oxygen species levels. The model is also suited for cell viability experiments under oxidative challenge, co-immunoprecipitation of KEAP1?CNRF2 complexes, and drug sensitivity/resistance profiling to identify or validate NRF2 inhibitors. These cells serve as a valuable resource for dissecting the KEAP1-NRF2 signaling axis in oncology research. For additional technical details or inquiries, please contact Ascent Research.
